Piet Ost is an associate professor at Ghent University, Ghent, Belgium and radiation oncologist at the Iridium Network, Antwerp, Belgium. He is an expert in the treatment of genitourinary malignancies with a focus on prostate and bladder cancers. His research focuses on the implementation of stereotactic body radiotherapy (SBRT), oligometastases and drug-radiotherapy trials. Dr Ost has led numerous clinical trials exploring the potential benefit of SBRT for oligometastases and radioimmunotherapy. He serves as a reviewer for several grant organizations and journals. He is a co-author of the ESMO clinical prostate cancer practice guidelines and the 2-yearly Advanced Prostate Cancer Consensus Conference. Dr Ost is the chair of the Radiation Oncology Scientific Council of the EORTC.
He received his M.D. degree at Ghent University in 2006, his PhD in 2011 and completed his radiation oncology training in 2012 at the same university.
Declaration of Interests
Consulting/Scientific Advisory: Bayer, Janssen, Curium, Ferring.
Grants for clinical research: Ferring, Merck, Varian, Bayer.